These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2421173)

  • 1. Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
    Veselý J; Pískala A
    Neoplasma; 1986; 33(1):3-10. PubMed ID: 2421173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
    Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
    Chabot GG; Momparler RL
    Cancer Treat Rep; 1984 Dec; 68(12):1483-7. PubMed ID: 6210142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
    Chou TC; Hutchinson DJ; Schmid FA; Philips FS
    Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.
    Grant S; Rauscher F; Margolin J; Cadman E
    Cancer Res; 1982 Feb; 42(2):519-24. PubMed ID: 6173114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4).
    Townsend A; Leclerc JM; Dutschman G; Cooney D; Cheng YC
    Cancer Res; 1985 Aug; 45(8):3522-8. PubMed ID: 2410096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
    Momparler RL; Momparler LF; Samson J
    Leuk Res; 1984; 8(6):1043-9. PubMed ID: 6083417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.
    Wilson VL; Jones PA; Momparler RL
    Cancer Res; 1983 Aug; 43(8):3493-6. PubMed ID: 6190553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
    Balzarini J; De Clercq E
    Mol Pharmacol; 1983 Jan; 23(1):175-81. PubMed ID: 6306422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW; Cheng YC; Schabel FM; Montgomery JA
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
    Presant CA; Valeriote F; Vietti TJ
    Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE; Selner M; Phillips JR
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effect of cytosine arabinoside and thiopurines.
    Valeriote F; Vietti T; Edelstein M
    Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
    Driscoll JS; Johns DG; Plowman J
    Invest New Drugs; 1985; 3(4):331-4. PubMed ID: 2417984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine.
    Neil GL; Berger AE; Bhuyan BK; DeSante DC
    Cancer Res; 1976 Mar; 36(3):1114-20. PubMed ID: 56229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.
    Dalal M; Plowman J; Breitman TR; Schuller HM; del Campo AA; Vistica DT; Driscoll JS; Cooney DA; Johns DG
    Cancer Res; 1986 Feb; 46(2):831-8. PubMed ID: 2416433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
    Lincoln T; Morrison P; Aroesty J; Carter G
    Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.